Ina Knerr1, Karen Patricia Coss2, Jürgen Kratzsch3, Ellen Crushell1, Anne Clark1, Peter Doran2, Yoon Shin4, Henning Stöckmann5, Pauline Mary Rudd5, Eileen Treacy1. 1. National Centre for Inherited Metabolic Disorders, Temple Street Children's University Hospital, Dublin, Ireland. 2. University College Dublin, Clinical Research Centre, Mater Misericordiae University Hospital, Dublin, Ireland. 3. Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany. 4. Molecular Genetics and Metabolism Laboratory, Munich, Germany. 5. The National Institute for Bioprocessing Research and Training, Blackrock, Co., Dublin, Ireland.
Abstract
BACKGROUND: Classical galactosemia is caused by severe galactose-1-phosphate uridyltransferase deficiency. Despite life-long galactose-restriction, many patients experience long-term complications. Intoxication by galactose and its metabolites as well as over-restriction of galactose may contribute to the pathophysiology. We provided temporary low-dose galactose supplements to patients. We assessed tolerance and potential beneficial effects with clinical monitoring and measurement of biochemical, endocrine, and IgG N-glycosylation profiles. METHODS: We enrolled 26 patients (8.6 ± 1.9 y). Thirteen were provided with 300 mg of galactose/day followed by 500 mg for 2 wk each (13 patient controls). RESULTS: We observed no clinical changes with the intervention. Temporary mild increase in galactose-1-phosphate occurred, but renal, liver, and bone biochemistry remained normal. Patients in the supplementation group had slightly higher leptin levels at the end of the study than controls. We identified six individuals as "responders" with an improved glycosylation pattern (decreased G0/G2 ratio, P < 0.05). There was a negative relationship between G0/G2 ratio and leptin receptor sOb-R in the supplementation group (P < 0.05). CONCLUSION: Temporary low-dose galactose supplementation in children over 5 y is well tolerated in the clinical setting. It leads to changes in glycosylation in "responders". We consider IgG N-glycan monitoring to be useful for determining individual optimum galactose intake.
BACKGROUND:Classical galactosemia is caused by severe galactose-1-phosphate uridyltransferase deficiency. Despite life-long galactose-restriction, many patients experience long-term complications. Intoxication by galactose and its metabolites as well as over-restriction of galactose may contribute to the pathophysiology. We provided temporary low-dose galactose supplements to patients. We assessed tolerance and potential beneficial effects with clinical monitoring and measurement of biochemical, endocrine, and IgG N-glycosylation profiles. METHODS: We enrolled 26 patients (8.6 ± 1.9 y). Thirteen were provided with 300 mg of galactose/day followed by 500 mg for 2 wk each (13 patient controls). RESULTS: We observed no clinical changes with the intervention. Temporary mild increase in galactose-1-phosphate occurred, but renal, liver, and bone biochemistry remained normal. Patients in the supplementation group had slightly higher leptin levels at the end of the study than controls. We identified six individuals as "responders" with an improved glycosylation pattern (decreased G0/G2 ratio, P < 0.05). There was a negative relationship between G0/G2 ratio and leptin receptor sOb-R in the supplementation group (P < 0.05). CONCLUSION: Temporary low-dose galactose supplementation in children over 5 y is well tolerated in the clinical setting. It leads to changes in glycosylation in "responders". We consider IgG N-glycan monitoring to be useful for determining individual optimum galactose intake.
Authors: Bianca Panis; Jaap A Bakker; Jean-Pierre J E Sels; Leo J M Spaapen; Luc J C van Loon; M Estela Rubio-Gozalbo Journal: Mol Genet Metab Date: 2006-04-18 Impact factor: 4.797
Authors: Maja Pucić; Ana Knezević; Jana Vidic; Barbara Adamczyk; Mislav Novokmet; Ozren Polasek; Olga Gornik; Sandra Supraha-Goreta; Mark R Wormald; Irma Redzić; Harry Campbell; Alan Wright; Nicholas D Hastie; James F Wilson; Igor Rudan; Manfred Wuhrer; Pauline M Rudd; Djuro Josić; Gordan Lauc Journal: Mol Cell Proteomics Date: 2011-06-08 Impact factor: 5.911
Authors: G T Berry; M Palmieri; K C Gross; P B Acosta; J A Henstenburg; A Mazur; R Reynolds; S Segal Journal: J Inherit Metab Dis Date: 1993 Impact factor: 4.982
Authors: L Varela-Lema; L Paz-Valinas; G Atienza-Merino; R Zubizarreta-Alberdi; R Vizoso Villares; M López-García Journal: J Inherit Metab Dis Date: 2016-04-26 Impact factor: 4.982
Authors: Henning Stockmann; Karen P Coss; M Estela Rubio-Gozalbo; Ina Knerr; Maria Fitzgibbon; Ashwini Maratha; James Wilson; Pauline Rudd; Eileen P Treacy Journal: JIMD Rep Date: 2015-09-30
Authors: Hugh-Owen Colhoun; Estela M Rubio Gozalbo; Annet M Bosch; Ina Knerr; Charlotte Dawson; Jennifer Brady; Marie Galligan; Karolina Stepien; Roisin O'Flaherty; C Catherine Moss; P Peter Barker; Maria Fitzgibbon; Peter P Doran; Eileen P Treacy Journal: Orphanet J Rare Dis Date: 2018-09-19 Impact factor: 4.123
Authors: M E Rubio-Gozalbo; M Haskovic; A M Bosch; B Burnyte; A I Coelho; D Cassiman; M L Couce; C Dawson; D Demirbas; T Derks; F Eyskens; M T Forga; S Grunewald; J Häberle; M Hochuli; A Hubert; H H Huidekoper; P Janeiro; J Kotzka; I Knerr; P Labrune; Y E Landau; J G Langendonk; D Möslinger; D Müller-Wieland; E Murphy; K Õunap; D Ramadza; I A Rivera; S Scholl-Buergi; K M Stepien; A Thijs; C Tran; R Vara; G Visser; R Vos; M de Vries; S E Waisbren; M M Welsink-Karssies; S B Wortmann; M Gautschi; E P Treacy; G T Berry Journal: Orphanet J Rare Dis Date: 2019-04-27 Impact factor: 4.123
Authors: Michel van Weeghel; Lindsey Welling; Eileen P Treacy; Ronald J A Wanders; Sacha Ferdinandusse; Annet M Bosch Journal: Orphanet J Rare Dis Date: 2018-08-24 Impact factor: 4.123